Clinical Trial Update: A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Lutetium-177 Octreotate Therapy for neuroendocrine tumors is currently recruiting. The study is sponsored by AHS Cancer Contro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• Lutetium-177 Octreotate Therapy (lutetium-177 dotatate)

Snippet

Sponsor: AHS Cancer Control Alberta | Conditions: Carcinoma, Neuroendocrine | Phase 2 | Status: RECRUITING